All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results VERU-111, 2022 0.30 [0.14; 0.64]
0.30 [0.14 ; 0.64 ] VERU-111, 2022 1 0% 150 NA not evaluable death D28detailed results ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
Aman, 2021 0.51 [0.27; 0.96]
Bennett-Guerrero, 2021 0.86 [0.24; 3.11]
CAN-COVID, 2020 0.67 [0.30; 1.50]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.02 [0.62; 1.68]
Fragoso-Saavedra (PISCO), 2020 0.32 [0.13; 0.80]
Gunst JD, 2021 0.99 [0.29; 3.42]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
ITAC, 2022 0.80 [0.42; 1.52]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Lanzoni, 2021 0.14 [0.02; 0.96]
Metcovid, 2020 0.92 [0.67; 1.28]
Mobarak S (DISCOVER), 2021 1.10 [0.77; 1.57]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
NIH NIAID ACTT-1, 2020 0.73 [0.52; 1.03]
O’Donnell, 2021 0.47 [0.21; 1.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Shi, 2020 0.53 [0.01; 27.55]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
Tang X, 2020 0.98 [0.93; 1.02]
University of Minnesota, 2020 1.29 [0.51; 3.26]
Zhang, 2020 0.50 [0.17; 1.50]
0.77 [0.68 ; 0.88 ] ACTT-2 (Kalil), 2020, Aman, 2021, Bennett-Guerrero, 2021, CAN-COVID, 2020, CONTAIN COVID-19, 2021, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021, HYDRA (Hernandez-Cardenas), 2021, ITAC, 2022, Kalil (ACTT-3), 2021, Lanzoni, 2021, Metcovid, 2020, Mobarak S (DISCOVER), 2021, NCT04412772 (ARCHITECTS), 0, NIH NIAID ACTT-1, 2020, O’Donnell, 2021, PlasmAr, 2020, Rosas (REMDACTA), 2021, Shi, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, STOP-COVID (Guimarães), 2021, Tang X, 2020, University of Minnesota, 2020, Zhang, 2020 29 42% 12,834 moderate critical death or transfer to ICUdetailed results BACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88]
Gunst JD, 2021 0.55 [0.26; 1.17]
Lopardo, 2021 0.65 [0.35; 1.22]
0.72 [0.48 ; 1.06 ] BACC Bay Tocilizumab Trial, 2020, Gunst JD, 2021, Lopardo, 2021 3 0% 688 moderate not evaluable deathsdetailed results ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
ACTIV-3/TICO LY-CoV555 , 2020 1.71 [0.56; 5.21]
ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
Aman, 2021 0.51 [0.27; 0.96]
BACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
CAN-COVID, 2020 0.67 [0.30; 1.50]
CAP-China (Wang et al.), 2020 1.10 [0.49; 2.45]
CAPE-COVID, 2020 0.45 [0.20; 1.02]
CCAP-2, 2021 2.03 [0.61; 6.77]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
EMPACTA, 2020 1.13 [0.54; 2.40]
Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79]
Gonzalez (HCQ), 2020 0.33 [0.06; 1.78]
Gonzalez (IVER), 2020 0.83 [0.23; 3.02]
Gunst JD, 2021 0.70 [0.20; 2.49]
HYCOVID, 2020 0.54 [0.21; 1.40]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
ITAC, 2022 0.80 [0.42; 1.52]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Kirti, 2021 0.12 [0.01; 2.36]
Lanzoni, 2021 0.11 [0.01; 0.93]
Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12]
Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50]
Libster, 2020 0.50 [0.09; 2.71]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
Lopardo, 2021 0.57 [0.24; 1.37]
Metcovid, 2020 0.92 [0.67; 1.28]
Mobarak S (DISCOVER), 2021 1.15 [0.80; 1.67]
Murai, 2020 1.53 [0.53; 4.43]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
NCT04442191, 2021 0.11 [0.00; 143.68]
NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84]
ORCHID, 2020 1.07 [0.54; 2.11]
O’Donnell, 2021 0.47 [0.21; 1.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
ProPAC-COVID, 2021 0.08 [0.00; 8.65]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Salehzadeh, 2020 1.00 [0.02; 51.41]
SAVE-MORE, 2021 0.45 [0.20; 0.99]
Shi, 2020 0.53 [0.01; 27.55]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
Synairgen SG016, 2020 0.16 [0.01; 3.31]
Tang X, 2020 0.98 [0.93; 1.02]
TEACH, 2020 1.07 [0.34; 3.37]
University of Minnesota, 2020 0.68 [0.11; 4.16]
Zhang, 2020 0.50 [0.17; 1.50]
0.78 [0.70 ; 0.87 ] ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ACTT-2 (Kalil), 2020, Aman, 2021, BACC Bay Tocilizumab Trial, 2020, Baldeon, 2022, Bennett-Guerrero, 2021, CAN-COVID, 2020, CAP-China (Wang et al.), 2020, CAPE-COVID, 2020, CCAP-2, 2021, CONTAIN COVID-19, 2021, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, EMPACTA, 2020, Fragoso-Saavedra (PISCO), 2020, Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, Gunst JD, 2021, HYCOVID, 2020, HYDRA (Hernandez-Cardenas), 2021, ITAC, 2022, Kalil (ACTT-3), 2021, Kirti, 2021, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Libster, 2020, LIVE-AIR (Temesgen), 2021, Lopardo, 2021, Metcovid, 2020, Mobarak S (DISCOVER), 2021, Murai, 2020, NCT04412772 (ARCHITECTS), 0, NCT04442191, 2021, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, PlasmAr, 2020, ProPAC-COVID, 2021, Rosas (REMDACTA), 2021, Salehzadeh, 2020, SAVE-MORE, 2021, Shi, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Tang X, 2020, TEACH, 2020, University of Minnesota, 2020, Zhang, 2020 55 32% 19,908 moderate critical deaths (time to event analysis only)detailed results ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79]
Gunst JD, 2021 0.70 [0.20; 2.49]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Lanzoni, 2021 0.11 [0.01; 0.93]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84]
PlasmAr, 2020 0.93 [0.47; 1.85]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Zhang, 2020 0.50 [0.17; 1.50]
0.74 [0.62 ; 0.87 ] ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTT-2 (Kalil), 2020, Baldeon, 2022, Bennett-Guerrero, 2021, COV-BARRIER, 2021, COVACTA (Rosas), 2020, Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021, HYDRA (Hernandez-Cardenas), 2021, Kalil (ACTT-3), 2021, Lanzoni, 2021, LIVE-AIR (Temesgen), 2021, NIH NIAID ACTT-1, 2020, PlasmAr, 2020, Rosas (REMDACTA), 2021, Zhang, 2020 17 27% 9,200 moderate low clinical deteriorationdetailed results BACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09]
CAP-China (Wang et al.), 2020 0.95 [0.55; 1.64]
CONTAIN COVID-19, 2021 0.94 [0.75; 1.18]
COV-BARRIER, 2021 1.12 [0.58; 2.16]
EMPACTA, 2020 0.55 [0.33; 0.92]
Libster, 2020 0.52 [0.29; 0.94]
SAVE-MORE, 2021 0.36 [0.26; 0.50]
STOP-COVID (Guimarães), 2021 0.54 [0.27; 1.07]
Synairgen SG016, 2020 0.50 [0.18; 1.38]
Tang X, 2020 1.00 [0.13; 7.45]
TEACH, 2020 1.80 [0.62; 5.21]
Zhang, 2020 0.40 [0.10; 1.65]
0.71 [0.52 ; 0.96 ] BACC Bay Tocilizumab Trial, 2020, CAP-China (Wang et al.), 2020, CONTAIN COVID-19, 2021, COV-BARRIER, 2021, EMPACTA, 2020, Libster, 2020, SAVE-MORE, 2021, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Tang X, 2020, TEACH, 2020, Zhang, 2020 12 68% 3,476 low low clinical improvementdetailed results ACTIV-3/TICO (tixa), 2022 1.08 [0.97; 1.20]
ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
BACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
CAN-COVID, 2020 1.39 [0.76; 2.54]
CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
COV-BARRIER, 2021 1.25 [1.04; 1.50]
COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
EMPACTA, 2020 1.15 [0.90; 1.47]
Gunst JD, 2021 1.14 [0.83; 1.57]
ITAC, 2022 1.06 [0.77; 1.45]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lopardo, 2021 1.61 [0.75; 3.49]
NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49]
ORCHID, 2020 1.02 [0.73; 1.42]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 0.81 [0.50; 1.31]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
Synairgen SG016, 2020 2.32 [1.07; 5.04]
Tang X, 2020 1.04 [0.67; 1.62]
1.13 [1.07 ; 1.19 ] ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, Bennett-Guerrero, 2021, CAN-COVID, 2020, CAP-China (Wang et al.), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, EMPACTA, 2020, Gunst JD, 2021, ITAC, 2022, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lopardo, 2021, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, PlasmAr, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Synairgen SG016, 2020, Tang X, 2020 24 5% 10,285 moderate low clinical improvement (14-day)detailed results ACTT-2 (Kalil), 2020 1.30 [1.03; 1.64]
CAP-China (Wang et al.), 2020 1.21 [0.64; 2.28]
COV-BARRIER, 2021 1.28 [1.05; 1.56]
COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09]
Kalil (ACTT-3), 2021 1.01 [0.79; 1.29]
ORCHID, 2020 1.02 [0.73; 1.42]
Tang X, 2020 1.33 [0.57; 3.11]
1.20 [1.07 ; 1.34 ] ACTT-2 (Kalil), 2020, CAP-China (Wang et al.), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, Kalil (ACTT-3), 2021, ORCHID, 2020, Tang X, 2020 7 0% 4,429 low not evaluable clinical improvement (28-day)detailed results Bennett-Guerrero, 2021 1.02 [0.25; 4.20]
CAP-China (Wang et al.), 2020 1.37 [0.79; 2.39]
COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
NIH NIAID ACTT-1, 2020 1.35 [1.03; 1.76]
ORCHID, 2020 0.97 [0.69; 1.37]
O’Donnell, 2021 1.38 [0.73; 2.61]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
Synairgen SG016, 2020 3.15 [1.39; 7.14]
1.30 [1.10 ; 1.52 ] Bennett-Guerrero, 2021, CAP-China (Wang et al.), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Synairgen SG016, 2020 10 1% 2,739 moderate low clinical improvement (7-day)detailed results ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
CAP-China (Wang et al.), 2020 0.99 [0.18; 5.51]
ITAC, 2022 1.06 [0.77; 1.45]
Kirti, 2021 0.90 [0.77; 1.06]
ORCHID, 2020 1.16 [0.84; 1.61]
0.95 [0.84 ; 1.08 ] ACTIV-3/TICO LY-CoV555 , 2020, CAP-China (Wang et al.), 2020, ITAC, 2022, Kirti, 2021, ORCHID, 2020 5 0% 1,726 moderate not evaluable clinical improvement (time to event analysis only)detailed results ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
EMPACTA, 2020 1.15 [0.90; 1.47]
Gunst JD, 2021 1.14 [0.83; 1.57]
HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54]
NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49]
ORCHID, 2020 0.97 [0.69; 1.36]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 1.00 [0.76; 1.32]
Shinkai, 2021 1.40 [0.91; 2.15]
Tang X, 2020 1.04 [0.67; 1.62]
1.12 [1.06 ; 1.19 ] ACTT-2 (Kalil), 2020, Bennett-Guerrero, 2021, CAP-China (Wang et al.), 2020, EMPACTA, 2020, Gunst JD, 2021, HYDRA (Hernandez-Cardenas), 2021, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, PlasmAr, 2020, Shinkai, 2021, Tang X, 2020 15 0% 5,581 moderate low death or ventilationdetailed results ACTT-2 (Kalil), 2020 0.69 [0.50; 0.95]
BACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81]
CAPE-COVID, 2020 0.71 [0.37; 1.35]
EMPACTA, 2020 0.56 [0.32; 0.97]
Fragoso-Saavedra (PISCO), 2020 0.46 [0.22; 0.96]
Gonzalez (HCQ), 2020 0.69 [0.22; 2.21]
Gonzalez (IVER), 2020 0.89 [0.30; 2.64]
HYCOVID, 2020 1.12 [0.45; 2.79]
LIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98]
ORCHID, 2020 1.13 [0.60; 2.13]
Rosas (REMDACTA), 2021 0.98 [0.72; 1.34]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94]
STOP-COVID (Guimarães), 2021 0.63 [0.41; 0.97]
Synairgen SG016, 2020 0.38 [0.09; 1.63]
0.73 [0.64 ; 0.84 ] ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, CAPE-COVID, 2020, EMPACTA, 2020, Fragoso-Saavedra (PISCO), 2020, Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, HYCOVID, 2020, LIVE-AIR (Temesgen), 2021, ORCHID, 2020, Rosas (REMDACTA), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020 14 0% 4,614 moderate low hospital dischargedetailed results ACTIV-3/TICO LY-CoV555 , 2020 0.97 [0.78; 1.20]
CAPE-COVID, 2020 1.67 [0.87; 3.19]
EMPACTA, 2020 1.16 [0.90; 1.49]
Fragoso-Saavedra (PISCO), 2020 1.13 [0.82; 1.55]
Gonzalez (HCQ), 2020 1.38 [0.46; 4.16]
Gonzalez (IVER), 2020 0.71 [0.15; 3.40]
HYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42]
Kirti, 2021 1.20 [0.73; 1.98]
Murai, 2020 0.99 [0.71; 1.38]
Rosas (REMDACTA), 2021 0.97 [0.79; 1.20]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09]
Synairgen SG016, 2020 1.63 [0.61; 4.35]
University of Minnesota, 2020 0.64 [0.37; 1.11]
1.06 [0.96 ; 1.18 ] ACTIV-3/TICO LY-CoV555 , 2020, CAPE-COVID, 2020, EMPACTA, 2020, Fragoso-Saavedra (PISCO), 2020, Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, HYDRA (Hernandez-Cardenas), 2021, Kirti, 2021, Murai, 2020, Rosas (REMDACTA), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Synairgen SG016, 2020, University of Minnesota, 2020 13 3% 3,512 moderate low hospitalizationdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
University of Minnesota, 2020 1.63 [0.94; 2.85]
1.58 [0.92 ; 2.70 ] Jagannathan, 2020, University of Minnesota, 2020 2 0% 325 moderate not evaluable mechanical ventilationdetailed results ACTT-2 (Kalil), 2020 0.64 [0.44; 0.93]
CAPE-COVID, 2020 0.95 [0.44; 2.04]
COVACTA (Rosas), 2020 0.67 [0.39; 1.14]
Fragoso-Saavedra (PISCO), 2020 0.85 [0.27; 2.62]
Gunst JD, 2021 2.27 [0.62; 8.26]
Kirti, 2021 0.20 [0.00; 8.69]
Metcovid, 2020 1.19 [0.56; 2.49]
Mobarak S (DISCOVER), 2021 1.52 [0.72; 3.19]
Murai, 2020 0.49 [0.21; 1.14]
O’Donnell, 2021 1.50 [0.47; 4.82]
PlasmAr, 2020 0.86 [0.39; 1.93]
SAVE-MORE, 2021 0.47 [0.03; 7.48]
Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48]
Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07]
University of Minnesota, 2020 1.34 [0.66; 2.73]
0.87 [0.68 ; 1.12 ] ACTT-2 (Kalil), 2020, CAPE-COVID, 2020, COVACTA (Rosas), 2020, Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021, Kirti, 2021, Metcovid, 2020, Mobarak S (DISCOVER), 2021, Murai, 2020, O’Donnell, 2021, PlasmAr, 2020, SAVE-MORE, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, University of Minnesota, 2020 15 18% 4,846 moderate low mechanical ventilation (time to event analysis only)detailed results Fragoso-Saavedra (PISCO), 2020 0.81 [0.27; 2.42]
Gunst JD, 2021 0.69 [0.14; 3.42]
0.77 [0.31 ; 1.90 ] Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021 2 0% 396 moderate not evaluable viral clearance detailed results Chaccour, 2020 0.92 [0.77; 1.09]
Jagannathan, 2020 0.81 [0.56; 1.18]
Tang X, 2020 1.78 [1.06; 3.00]
1.03 [0.73 ; 1.47 ] Chaccour, 2020, Jagannathan, 2020, Tang X, 2020 3 69% 230 moderate not evaluable viral clearance (time to event analysis only)detailed results Jagannathan, 2020 0.81 [0.56; 1.18]
Tang X, 2020 1.78 [1.06; 3.00]
1.18 [0.54 ; 2.54 ] Jagannathan, 2020, Tang X, 2020 2 83% 206 moderate not evaluable viral clearance by day 7detailed results Chaccour, 2020 0.92 [0.77; 1.09]
Kirti, 2021 0.80 [0.43; 1.50]
0.91 [0.77 ; 1.08 ] Chaccour, 2020, Kirti, 2021 2 0% 136 low not evaluable ICU admissiondetailed results COVACTA (Rosas), 2020 0.48 [0.25; 0.94]
Gunst JD, 2021 0.80 [0.34; 1.90]
Kirti, 2021 0.90 [0.30; 2.70]
Libster, 2020 0.33 [0.07; 1.58]
Lopardo, 2021 0.67 [0.35; 1.28]
Murai, 2020 0.71 [0.37; 1.37]
ProPAC-COVID, 2021 1.24 [0.26; 5.80]
Tang X, 2020 1.00 [0.13; 7.45]
0.66 [0.49 ; 0.91 ] COVACTA (Rosas), 2020, Gunst JD, 2021, Kirti, 2021, Libster, 2020, Lopardo, 2021, Murai, 2020, ProPAC-COVID, 2021, Tang X, 2020 8 0% 1,349 moderate not evaluable off oxygenationdetailed results HYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51]
0.98 [0.64 ; 1.51 ] HYDRA (Hernandez-Cardenas), 2021 1 0% 214 NA not evaluable recoverydetailed results ACTIV-3 (BRII-196 and BRII-198), 2021 1.08 [0.88; 1.32]
ACTIV-3/ TICO (sotrovimab), 2021 1.12 [0.91; 1.37]
ACTIV-3/TICO LY-CoV555 , 2020 1.06 [0.77; 1.46]
COV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20]
Crippa (CANDIDATE), 2021 0.54 [0.15; 1.94]
Gunst JD, 2021 1.18 [0.87; 1.61]
Lanzoni, 2021 3.46 [1.05; 11.35]
Mobarak S (DISCOVER), 2021 0.97 [0.89; 1.05]
Synairgen SG016, 2020 2.19 [1.03; 4.67]
1.10 [0.97 ; 1.26 ] ACTIV-3 (BRII-196 and BRII-198), 2021, ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO LY-CoV555 , 2020, COV-BARRIER (critically ill), 2022, Crippa (CANDIDATE), 2021, Gunst JD, 2021, Lanzoni, 2021, Mobarak S (DISCOVER), 2021, Synairgen SG016, 2020 9 42% 2,636 low serious AE leading to drug discontinuationdetailed results CAP-China (Wang et al.), 2020 2.43 [0.79; 7.45]
2.43 [0.79 ; 7.45 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable composite safety outcome detailed results ACTIV-3/TICO LY-CoV555 , 2020 1.56 [0.78; 3.11]
1.56 [0.78 ; 3.11 ] ACTIV-3/TICO LY-CoV555 , 2020 1 0% 314 NA not evaluable related AE (TRAE)detailed results Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93]
1.26 [0.14 ; 11.07 ] Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 2 0% 25 moderate not evaluable serious adverse eventsdetailed results BACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53]
CAN-COVID, 2020 0.73 [0.45; 1.19]
CAP-China (Wang et al.), 2020 0.64 [0.33; 1.23]
COVACTA (Rosas), 2020 0.81 [0.54; 1.22]
Gunst JD, 2021 1.84 [0.79; 4.30]
ITAC, 2022 0.98 [0.66; 1.46]
Jagannathan, 2020 1.00 [0.14; 7.34]
Lanzoni, 2021 0.10 [0.01; 0.69]
Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12]
Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51]
Murai, 2020 0.99 [0.02; 50.39]
NIH NIAID ACTT-1, 2020 0.72 [0.54; 0.96]
ORCHID, 2020 1.26 [0.56; 2.84]
O’Donnell, 2021 0.64 [0.35; 1.17]
PlasmAr, 2020 1.40 [0.78; 2.51]
Rosas (REMDACTA), 2021 0.83 [0.59; 1.18]
Shi, 2020 1.08 [0.04; 32.96]
Shinkai, 2021 2.80 [0.14; 56.95]
0.90 [0.77 ; 1.05 ] BACC Bay Tocilizumab Trial, 2020, CAN-COVID, 2020, CAP-China (Wang et al.), 2020, COVACTA (Rosas), 2020, Gunst JD, 2021, ITAC, 2022, Jagannathan, 2020, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Murai, 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, PlasmAr, 2020, Rosas (REMDACTA), 2021, Shi, 2020, Shinkai, 2021 18 16% 6,020 moderate low superinfectiondetailed results ACTT-2 (Kalil), 2020 0.50 [0.32; 0.79]
CAPE-COVID, 2020 0.81 [0.49; 1.34]
Metcovid, 2020 0.98 [0.65; 1.47]
0.74 [0.49 ; 1.11 ] ACTT-2 (Kalil), 2020, CAPE-COVID, 2020, Metcovid, 2020 3 57% 1,575 low not evaluable adverse eventsdetailed results Chaccour, 2020 1.00 [0.20; 5.07]
COVACTA (Rosas), 2020 0.87 [0.52; 1.45]
Gunst JD, 2021 0.80 [0.43; 1.51]
Jagannathan, 2020 1.33 [0.63; 2.78]
Lanzoni, 2021 0.18 [0.02; 1.95]
Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69]
Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27]
Murai, 2020 1.99 [0.07; 59.94]
ORCHID, 2020 1.42 [0.87; 2.34]
Rosas (REMDACTA), 2021 1.32 [0.92; 1.89]
Shi, 2020 0.88 [0.38; 2.03]
Shinkai, 2021 19.54 [7.77; 49.11]
Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71]
Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01]
TEACH, 2020 1.16 [0.55; 2.42]
1.24 [0.85 ; 1.82 ] Chaccour, 2020, COVACTA (Rosas), 2020, Gunst JD, 2021, Jagannathan, 2020, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Murai, 2020, ORCHID, 2020, Rosas (REMDACTA), 2021, Shi, 2020, Shinkai, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, TEACH, 2020 15 70% 3,080 moderate low deep vein thrombosisdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
NIH NIAID ACTT-1, 2020 0.64 [0.23; 1.81]
0.62 [0.23 ; 1.64 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable elevated liver enzymesdetailed results CAP-China (Wang et al.), 2020 0.36 [0.13; 1.01]
NIH NIAID ACTT-1, 2020 0.67 [0.38; 1.18]
0.58 [0.34 ; 0.97 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 6% 1,296 moderate not evaluable hyperbilirubinemiadetailed results CAP-China (Wang et al.), 2020 1.09 [0.42; 2.79]
NIH NIAID ACTT-1, 2020 0.84 [0.30; 2.34]
0.97 [0.48 ; 1.93 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 low not evaluable pulmonary embolismdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
NIH NIAID ACTT-1, 2020 0.96 [0.19; 4.80]
0.82 [0.20 ; 3.29 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable renal impairmentdetailed results CAP-China (Wang et al.), 2020 1.01 [0.03; 30.33]
NIH NIAID ACTT-1, 2020 1.02 [0.64; 1.61]
1.02 [0.64 ; 1.61 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-26 19:58 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290